Lantheus Holdings (LNTH) Total Current Liabilities (2014 - 2026)
Lantheus Holdings' (LNTH) quarterly Total Current Liabilities came in at $333.2 million in Q1 2026, up 34.34% year-on-year from $248.0 million in Q1 2025, and little changed on a QoQ basis from $333.4 million in Q4 2025.
Lantheus Holdings (LNTH) Total Current Liabilities (2014 - 2026) Analysis & Trends
Lantheus Holdings (LNTH) has 13 years of Total Current Liabilities data on file, last reported at $333.2 million in Q1 2026.
- On a quarterly basis, Total Current Liabilities rose 34.34% year-over-year to $333.2 million in Q1 2026; TTM through Mar 2026 was $333.2 million, a 34.34% increase from a year earlier, with the FY2025 full-year figure at $333.4 million, up 38.62% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $333.2 million, roughly flat from $333.4 million in the prior quarter.
- Over the last five years, Total Current Liabilities for LNTH reached as high as $784.1 million in Q3 2024 and fell as low as $154.0 million in Q2 2023.
- Historically, Total Current Liabilities has averaged $278.9 million across 5 years, with a median of $247.7 million in 2022.
- Across the five-year window, Total Current Liabilities soared 343.98% in 2024 and slumped 55.76% in 2025, its largest moves.
- Year by year, Total Current Liabilities stood at $247.7 million in 2022, then declined by 24.36% to $187.4 million in 2023, then climbed by 28.38% to $240.5 million in 2024, then jumped by 38.62% to $333.4 million in 2025, then dropped by 0.08% to $333.2 million in 2026.
- Per Business Quant data, the three most recent Total Current Liabilities figures were $333.2 million in Q1 2026, $333.4 million in Q4 2025, and $346.8 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 6.56 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 13.53 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 2.05 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 18.06 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 599.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 13.17 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 6.81 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 831.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 1.66 Bn |
| 10 | Lantheus Holdings | 6.72 Bn | 6.22 Bn | 230.92 Mn | 333.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 333.17 Mn |
| Dec 31, 2025 | 333.42 Mn |
| Sep 30, 2025 | 346.84 Mn |
| Jun 30, 2025 | 280.13 Mn |
| Mar 31, 2025 | 248.00 Mn |
| Dec 31, 2024 | 240.53 Mn |
| Sep 30, 2024 | 784.08 Mn |
| Jun 30, 2024 | 263.29 Mn |
| Mar 31, 2024 | 237.20 Mn |
| Dec 31, 2023 | 187.35 Mn |
| Sep 30, 2023 | 176.60 Mn |
| Jun 30, 2023 | 154.04 Mn |
| Mar 31, 2023 | 276.39 Mn |
| Dec 31, 2022 | 247.70 Mn |
| Sep 30, 2022 | 235.98 Mn |
| Jun 30, 2022 | 219.02 Mn |
| Mar 31, 2022 | 177.66 Mn |
| Dec 31, 2021 | 90.50 Mn |
| Sep 30, 2021 | 76.90 Mn |
| Jun 30, 2021 | 73.83 Mn |